TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD—A Prospective Case–Control Study
Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, has been identified as a possible risk factor for COVID-19 severity. However, the immunological mechanisms by which NAFLD exacerbates COVID-19 remain unknown. Transforming growth factor-beta 1...
Main Authors: | Frano Susak, Nina Vrsaljko, Adriana Vince, Neven Papic |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/11/6/1571 |
Similar Items
-
NAFLD: Mechanisms, Treatments, and Biomarkers
by: Fatiha Nassir
Published: (2022-06-01) -
Pro-Inflammatory Adipokine and Cytokine Profiles in the Saliva of Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)—A Pilot Study
by: Beata Zyśk, et al.
Published: (2023-02-01) -
Treatments for NAFLD: State of Art
by: Alessandro Mantovani, et al.
Published: (2021-02-01) -
Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Nelson Kei, et al.
Published: (2023-09-01) -
Preventative and Therapeutic Effects of Astaxanthin on NAFLD
by: Nor Hafiza Sayuti, et al.
Published: (2023-08-01)